Table 1.
Mass spectrometry parameters for rivaroxaban monitoring.
Fig 1.
The matrix effect according to sample type.
The chromatograms shows in blue, pink, red and green the multiple reaction monitoring (MRM) for normal, lipemic, hemolytic and icteric samples, respectively. Figs A, B and C shows the MRM transitions for rivaroxaban (435.9 → 144.9 and 435. 9 → 233.1) and for IS (440.1 → 144.9) in drug-free samples and D, E and F in samples spiked with rivaroxaban (400 ng/mL) and rivaroxaban-d4 (67 ng/mL).
Table 2.
Number of samples according to sample type.
Fig 2.
The matrix effect by infusion method.
The chromatogram shows in blue, red and green the multiple reaction monitoring (MRM) for quantitative and qualitative detection of rivaroxaban and Internal Standard (IS), respectively. The orange dashed line highlight the rivaroxaban retention time expected.
Table 3.
Intra-day and inter-day precision and accuracy values of plasmatic rivaroxaban.
Table 4.
Stability data of rivaroxaban in human plasma.
Fig 3.
Method comparison HPLC-MS/MS assay and the anti-Xa assay (n = 96): (A) Spearman correlation of rivaroxaban results obtained by the HPLC-MS/MS assay and the anti-Xa assay used for rivaroxaban measurement from STAGO performed on the STA-R Evolution® analyzer; (B) Bland-Altman analyses.
Fig 4.
Method comparison HPLC-MS/MS assay and the anti-Xa assay from external laboratory (n = 19): (A) Spearman correlation of rivaroxaban results obtained by the HPLC-MS/MS assay and the anti-Xa assay used for rivaroxaban measurement from external laboratory; (B) Bland-Altman analyses.
Fig 5.
Interlaboratorial anti-Xa method comparison (n = 19).
(A) Interlaboratorial comparison of rivaroxaban results obtained by anti-Xa activity assays; (B) Bland-Altman analyses.
Table 5.
Rivaroxaban HPLC-MS/MS method comparison.